{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:32:04Z","timestamp":1789104724857,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"DOI":"10.1186\/s12880-025-01557-9","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T16:21:51Z","timestamp":1737390111000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Which PSMA PET\/CT interpretation criteria most effectively diagnose prostate cancer? a retrospective cohort study"],"prefix":"10.1186","volume":"25","author":[{"given":"Le","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxin","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luoping","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanchun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyuan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"issue":"1","key":"1557_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A, Cancer statistics. CA Cancer J Clin 2024 Jan-Feb. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin 2024 Jan-Feb"},{"issue":"7","key":"1557_CR2","first-page":"1807","volume":"54","author":"RS Israeli","year":"1994","unstructured":"Israeli RS, Powell CT, Corr JG, et al. Expression of the prostate-specific membrane antigen. Cancer Res. 1994;54(7):1807\u201311.","journal-title":"Cancer Res"},{"issue":"1","key":"1557_CR3","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3(1):81\u20135.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 2","key":"1557_CR4","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.2967\/jnumed.116.186767","volume":"58","author":"M Eiber","year":"2017","unstructured":"Eiber M, Fendler WP, Rowe SP, et al. Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. J Nucl Med. 2017;58(Suppl 2):S67\u201376.","journal-title":"J Nucl Med"},{"issue":"10","key":"1557_CR5","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.2967\/jnumed.117.191031","volume":"58","author":"SM Schwarzenboeck","year":"2017","unstructured":"Schwarzenboeck SM, Rauscher I, Bluemel C, et al. PSMA ligands for PET imaging of prostate Cancer. J Nucl Med. 2017;58(10):1545\u201352.","journal-title":"J Nucl Med"},{"key":"1557_CR6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1053\/j.semnuclmed.2016.04.004","volume":"46","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Afshar-Oromieh A, Kopka K, et al. Current status of prostate-specific membrane antigen targeting in nuclear medicine: clinical translation of chelator containing prostate-specific membrane antigen ligands into diagnostics and therapy for prostate cancer. Semin Nucl Med. 2016;46:405\u201318.","journal-title":"Semin Nucl Med"},{"key":"1557_CR7","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","volume":"70","author":"M Perera","year":"2016","unstructured":"Perera M, Papa N, Christidis D, et al. Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and Meta-analysis. Eur Urol. 2016;70:926\u201337.","journal-title":"Eur Urol"},{"issue":"8","key":"1557_CR8","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1007\/s00259-019-04620-0","volume":"47","author":"P Donato","year":"2020","unstructured":"Donato P, Morton A, Yaxley J, et al. (68)Ga-PSMA PET\/CT better characterises localised prostate cancer after MRI and transperineal prostate biopsy: is (68)Ga-PSMA PET\/CT guided biopsy the future? Eur J Nucl Med Mol Imaging. 2020;47(8):1843\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1557_CR9","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2967\/jnumed.115.169243","volume":"57","author":"K Rahbar","year":"2016","unstructured":"Rahbar K, Weckesser M, Huss S, et al. Correlation of Intraprostatic Tumor Extent with \u2076\u2078Ga-PSMA distribution in patients with prostate Cancer. J Nucl Med. 2016;57(4):563\u20137.","journal-title":"J Nucl Med"},{"issue":"1","key":"1557_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/bju.14858","volume":"126","author":"AA Kalapara","year":"2020","unstructured":"Kalapara AA, Nzenza T, Pan HYC, et al. Detection and localisation of primary prostate cancer using (68) gallium prostate-specific membrane antigen positron emission tomography\/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology. BJU Int. 2020;126(1):83\u201390.","journal-title":"BJU Int"},{"issue":"1","key":"1557_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.7150\/thno.16638","volume":"7","author":"C Zamboglou","year":"2017","unstructured":"Zamboglou C, Drendel V, Jilg CA, et al. Comparison of (68)Ga-HBED-CC PSMA-PET\/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology. Theranostics. 2017;7(1):228\u201337.","journal-title":"Theranostics"},{"issue":"6","key":"1557_CR12","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1007\/s00259-017-3670-z","volume":"44","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Eiber M, Beheshti M, et al. 68Ga-PSMA PET\/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44(6):1014\u201324.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"1557_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate Cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243\u201362.","journal-title":"Eur Urol"},{"key":"1557_CR14","doi-asserted-by":"publisher","first-page":"7645","DOI":"10.1158\/1078-0432.CCR-11-1357","volume":"17","author":"Y Chen","year":"2011","unstructured":"Chen Y, Pullambhatla M, Foss CA, et al. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3- carbonyl)-amino]-pentyl}-ureido)-pen tanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res. 2011;17:7645\u201353.","journal-title":"Clin Cancer Res"},{"key":"1557_CR15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2967\/jnumed.116.181768","volume":"58","author":"J Cardinale","year":"2017","unstructured":"Cardinale J, Sch\u00e4fer M, Bene\u0161ov\u00e1 M, et al. Preclinical evaluation of 18F-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging. J Nucl Med. 2017;58:425\u201331.","journal-title":"J Nucl Med"},{"key":"1557_CR16","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s11307-015-0850-8","volume":"17","author":"Z Szabo","year":"2015","unstructured":"Szabo Z, Mena E, Rowe SP, et al. Initial evaluation of [(18)F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015;17:565\u201374.","journal-title":"Mol Imaging Biol"},{"key":"1557_CR17","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","volume":"44","author":"FL Giesel","year":"2017","unstructured":"Giesel FL, Hadaschik B, Cardinale J, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678\u201388.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1557_CR18","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.eururo.2017.10.027","volume":"73","author":"SP Rowe","year":"2018","unstructured":"Rowe SP, Pienta KJ, Pomper MG, et al. PSMA-RADS Version 1.0: a step towards standardizing the interpretation and reporting of PSMA-targeted PET imaging studies. Eur Urol. 2018;73(4):485\u20137.","journal-title":"Eur Urol"},{"issue":"3","key":"1557_CR19","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","volume":"59","author":"M Eiber","year":"2018","unstructured":"Eiber M, Herrmann K, Calais J, et al. Prostate Cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-Ligand PET\/CT. J Nucl Med. 2018;59(3):469\u201378.","journal-title":"J Nucl Med"},{"issue":"5","key":"1557_CR20","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert R, Emmett L, Rowe SP, et al. Second Version of the prostate Cancer molecular imaging standardized evaluation Framework including response evaluation for clinical trials (PROMISE V2). Eur Urol. 2023;83(5):405\u201312.","journal-title":"Eur Urol"},{"issue":"2","key":"1557_CR21","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s00330-023-10083-7","volume":"34","author":"F Grawe","year":"2024","unstructured":"Grawe F, Blom F, Winkelmann M, et al. Reliability and practicability of PSMA-RADS 1.0 for structured reporting of PSMA-PET\/CT scans in prostate cancer patients. Eur Radiol. 2024;34(2):1157\u201366.","journal-title":"Eur Radiol"},{"issue":"3","key":"1557_CR22","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/RLU.0000000000004524","volume":"48","author":"RA Bundschuh","year":"2023","unstructured":"Bundschuh RA, L\u00fctje S, Bundschuh L, Lapa C, et al. High interobserver agreement on PSMA PET\/CT even in the absence of Clinical Data. Clin Nucl Med. 2023;48(3):207\u201312.","journal-title":"Clin Nucl Med"},{"issue":"12","key":"1557_CR23","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.2967\/jnumed.118.217588","volume":"59","author":"RA Werner","year":"2018","unstructured":"Werner RA, Bundschuh RA, Bundschuh L, et al. Interobserver Agreement for the standardized reporting system PSMA-RADS 1.0 on 18F-DCFPyL PET\/CT imaging. J Nucl Med. 2018;59(12):1857\u201364.","journal-title":"J Nucl Med"},{"issue":"8","key":"1557_CR24","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1097\/MNM.0000000000001219","volume":"41","author":"E Demirci","year":"2020","unstructured":"Demirci E, Akyel R, Caner B, et al. Interobserver and intraobserver agreement on prostate-specific membrane antigen PET\/CT images according to the miTNM and PSMA-RADS criteria. Nucl Med Commun. 2020;41(8):759\u201367.","journal-title":"Nucl Med Commun"},{"issue":"1","key":"1557_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13550-020-0596-4","volume":"10","author":"C Derwael","year":"2020","unstructured":"Derwael C, Lavergne O, Lovinfosse P, et al. Interobserver agreement of [68Ga]Ga-PSMA-11 PET\/CT images interpretation in men with newly diagnosed prostate cancer. EJNMMI Res. 2020;10(1):15.","journal-title":"EJNMMI Res"},{"key":"1557_CR26","doi-asserted-by":"crossref","unstructured":"Karahan \u015een NP, Aksu A, Bozkurt O, Tuna EB, Kaya G\u00c7. Interreader agreement in evaluation of 68Ga-PSMA PET\/CT at the time of initial staging: comparison of the three evaluation criteria in the pretreatment risk groups. Nucl Med Commun. 2022;43(1):86\u201391.","DOI":"10.1097\/MNM.0000000000001485"},{"key":"1557_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13550-024-01152-z","volume":"14","author":"ML Donswijk","year":"2024","unstructured":"Donswijk ML, Ettema RH, van der Gaag S, et al. The intra- and interobserver variability of PSMA-expression scores in patients with primary prostate cancer. EJNMMI Res. 2024;14:99.","journal-title":"EJNMMI Res"},{"issue":"7","key":"1557_CR28","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1007\/s00345-020-03490-8","volume":"39","author":"Y Bodar","year":"2021","unstructured":"Bodar Y, Jansen B, van der Voorn JP, et al. Detection of prostate cancer with (18)F-DCFPyL PET\/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial. World J Urol. 2021;39(7):2439\u201346.","journal-title":"World J Urol"},{"issue":"11","key":"1557_CR29","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.2967\/jnumed.116.172627","volume":"57","author":"WP Fendler","year":"2016","unstructured":"Fendler WP, Schmidt DF, Wenter V, et al. 68Ga-PSMA PET\/CT detects the location and extent of primary prostate Cancer. J Nucl Med. 2016;57(11):1720\u20135.","journal-title":"J Nucl Med"},{"issue":"2","key":"1557_CR30","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00259-020-04863-2","volume":"48","author":"L Zhang","year":"2021","unstructured":"Zhang L, Li WC, Xu Z, et al. (68)Ga-PSMA PET\/CT targeted biopsy for the diagnosis of clinically significant prostate cancer compared with transrectal ultrasound guided biopsy: a prospective randomized single-centre study. Eur J Nucl Med Mol Imaging. 2021;48(2):483\u201392.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1557_CR31","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2967\/jnumed.119.234187","volume":"61","author":"J Kuten","year":"2020","unstructured":"Kuten J, Fahoum I, Savin Z, et al. Head-to-Head comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET\/CT in staging prostate Cancer using histopathology and Immunohistochemical Analysis as a reference Standard. J Nucl Med. 2020;61(4):527\u201332.","journal-title":"J Nucl Med"},{"issue":"7","key":"1557_CR32","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.2967\/jnumed.117.204669","volume":"59","author":"FL Giesel","year":"2018","unstructured":"Giesel FL, Will L, Lawal I, et al. Intraindividual comparison of 18F-PSMA-1007 and 18F-DCFPyL PET\/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma: a pilot study. J Nucl Med. 2018;59(7):1076\u201380.","journal-title":"J Nucl Med"},{"issue":"9","key":"1557_CR33","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.2967\/jnumed.119.235333","volume":"61","author":"C Liu","year":"2020","unstructured":"Liu C, Liu T, Zhang Z, et al. (68)Ga-PSMA PET\/CT combined with PET\/Ultrasound-Guided prostate biopsy can diagnose clinically significant prostate Cancer in men with previous negative biopsy results. J Nucl Med. 2020;61(9):1314\u20139.","journal-title":"J Nucl Med"},{"issue":"11","key":"1557_CR34","first-page":"1644","volume":"63","author":"L Emmett","year":"2022","unstructured":"Emmett L, Papa N, Buteau J, et al. The PRIMARY score: using Intraprostatic 68Ga-PSMA PET\/CT patterns to optimize prostate Cancer diagnosis. J Nucl Med. 2022;63(11):1644\u201350.","journal-title":"J Nucl Med"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-025-01557-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-025-01557-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-025-01557-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T16:21:54Z","timestamp":1737390114000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedimaging.biomedcentral.com\/articles\/10.1186\/s12880-025-01557-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1557"],"URL":"https:\/\/doi.org\/10.1186\/s12880-025-01557-9","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,20]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study complies with the Declaration of Helsinki, ensuring the anonymity and security of data, and has been approved by the Ethics Committee of Shanxi Bethune Hospital (approval number: YXLL-2024-196). Informed consent was obtained from each participants through a mail-based process.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}